<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1B116AEE-BBD8-4B73-93CF-DCB8A5573C94"><gtr:id>1B116AEE-BBD8-4B73-93CF-DCB8A5573C94</gtr:id><gtr:name>National University of Singapore</gtr:name><gtr:address><gtr:line1>National University of Singapore</gtr:line1><gtr:line2>10 Kent Ridge Crescent</gtr:line2><gtr:line4>Singapore</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Singapore</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Oncology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1B116AEE-BBD8-4B73-93CF-DCB8A5573C94"><gtr:id>1B116AEE-BBD8-4B73-93CF-DCB8A5573C94</gtr:id><gtr:name>National University of Singapore</gtr:name><gtr:address><gtr:line1>National University of Singapore</gtr:line1><gtr:line2>10 Kent Ridge Crescent</gtr:line2><gtr:line4>Singapore</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Singapore</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/584EC7A6-0F03-413E-A444-AD288D6E29DC"><gtr:id>584EC7A6-0F03-413E-A444-AD288D6E29DC</gtr:id><gtr:firstName>Craig</gtr:firstName><gtr:otherNames>Nigel</gtr:otherNames><gtr:surname>Robson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/317B54AA-F9F9-497E-BABD-11785B2985E5"><gtr:id>317B54AA-F9F9-497E-BABD-11785B2985E5</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/95D46800-A4DF-40AC-8FD3-7EAF5194B22C"><gtr:id>95D46800-A4DF-40AC-8FD3-7EAF5194B22C</gtr:id><gtr:firstName>Norman</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Maitland</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4C053C1D-B970-4529-A539-B4FD6FE35A73"><gtr:id>4C053C1D-B970-4529-A539-B4FD6FE35A73</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Buttle</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B15BB6F0-B3C8-4D34-949E-ECCBEDFF79C7"><gtr:id>B15BB6F0-B3C8-4D34-949E-ECCBEDFF79C7</gtr:id><gtr:firstName>V</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Collins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7FB22B57-F9DC-4560-B487-3019E7738D93"><gtr:id>7FB22B57-F9DC-4560-B487-3019E7738D93</gtr:id><gtr:firstName>Noel</gtr:firstName><gtr:otherNames>W</gtr:otherNames><gtr:surname>Clarke</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9DE4BE6A-05F1-4AC6-A3EC-B4F33EA96180"><gtr:id>9DE4BE6A-05F1-4AC6-A3EC-B4F33EA96180</gtr:id><gtr:firstName>George</gtr:firstName><gtr:surname>DaveySmith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/90A15408-44B8-48CC-B14D-C50AE09A2638"><gtr:id>90A15408-44B8-48CC-B14D-C50AE09A2638</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>Geoffrey</gtr:otherNames><gtr:surname>Mills</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9EB733BA-34E5-4363-A1BF-C148F754B223"><gtr:id>9EB733BA-34E5-4363-A1BF-C148F754B223</gtr:id><gtr:firstName>Dylan Richard</gtr:firstName><gtr:surname>Edwards</gtr:surname><gtr:orcidId>0000-0002-3292-2064</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E21F9419-E970-4374-AAA6-C0C97401C46E"><gtr:id>E21F9419-E970-4374-AAA6-C0C97401C46E</gtr:id><gtr:firstName>Jenny</gtr:firstName><gtr:surname>Donovan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DA6027C5-52B9-4EC0-A72B-6EB6849E3381"><gtr:id>DA6027C5-52B9-4EC0-A72B-6EB6849E3381</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Oliver</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/63E0AEE1-6D8D-4425-A06A-F4A943FFAF21"><gtr:id>63E0AEE1-6D8D-4425-A06A-F4A943FFAF21</gtr:id><gtr:firstName>David Edgar</gtr:firstName><gtr:surname>Neal</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9AB8721B-1946-4A53-BF8C-4DF936AB232C"><gtr:id>9AB8721B-1946-4A53-BF8C-4DF936AB232C</gtr:id><gtr:firstName>Colby</gtr:firstName><gtr:surname>Eaton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/642A6BB7-AF02-4518-A376-107C0BB4D6D1"><gtr:id>642A6BB7-AF02-4518-A376-107C0BB4D6D1</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Croucher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7B20BBFF-566D-45C5-BE91-3D88F987F242"><gtr:id>7B20BBFF-566D-45C5-BE91-3D88F987F242</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:surname>Booth</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/68B30430-BDB6-4D32-B1E9-42980EB7D266"><gtr:id>68B30430-BDB6-4D32-B1E9-42980EB7D266</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Hawkins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/16E0D003-6526-4F96-804C-4BF1B1023C6D"><gtr:id>16E0D003-6526-4F96-804C-4BF1B1023C6D</gtr:id><gtr:firstName>Hing</gtr:firstName><gtr:otherNames>Yip</gtr:otherNames><gtr:surname>Leung</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/67CB7C87-1027-4BD0-9E1F-C5EC6D83C319"><gtr:id>67CB7C87-1027-4BD0-9E1F-C5EC6D83C319</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Martin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2CC350A2-8EFD-4136-8F1D-56ADBE49E1DC"><gtr:id>2CC350A2-8EFD-4136-8F1D-56ADBE49E1DC</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Gunnell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D1F31B91-E3F9-472C-84F4-9DEF9BC5028F"><gtr:id>D1F31B91-E3F9-472C-84F4-9DEF9BC5028F</gtr:id><gtr:firstName>Vincent</gtr:firstName><gtr:surname>Gnanpragasam</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/61F36905-19EC-433A-B92D-F2A2B2D01943"><gtr:id>61F36905-19EC-433A-B92D-F2A2B2D01943</gtr:id><gtr:firstName>Murray</gtr:firstName><gtr:surname>Stewart</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/165691B8-AFD5-48DE-89CC-512CE600302C"><gtr:id>165691B8-AFD5-48DE-89CC-512CE600302C</gtr:id><gtr:firstName>Herbie</gtr:firstName><gtr:surname>Newell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/919C856C-451C-40F1-A5E3-90742AEA6997"><gtr:id>919C856C-451C-40F1-A5E3-90742AEA6997</gtr:id><gtr:firstName>F</gtr:firstName><gtr:surname>Hamdy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E504E398-B748-4347-8610-49A4168A3384"><gtr:id>E504E398-B748-4347-8610-49A4168A3384</gtr:id><gtr:firstName>Gillian</gtr:firstName><gtr:surname>Murphy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500966"><gtr:id>F3045258-1D21-4189-BD51-B1D15232AF6D</gtr:id><gtr:title>ProMPT (Prostate Cancer: Mechanisms of Progression and Treatment)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500966</gtr:grantReference><gtr:abstractText>Members of our group are actively involved with a number of external stakeholders including the Department of Health (England), the HEFCE and major national charities and scientific societies. We regularly report in the media on prostate cancer matters of topical interest and have actively influenced UK Health Policy with respect to screening, configuration of services for men with prostate cancer, quality control with respect to surgical and radio-therapeutic treatments, and prostate biopsy. Each of the clinically active members has regular interaction with local and national patient groups for prostate cancer</gtr:abstractText><gtr:technicalSummary>ProMPT is a collaborative translational research group based in six UK universities studying advanced and progressing prostate cancer. Our aims are to study the molecular pathology of hormone resistant and metastatic prostate cancer in man to identify potential targets, which we are studying and validating in human tissue and human cell models that we have developed. Our drug development and bio-repository programmes both ensure that we constantly focus on potential benefit to patients. The main bio-science discovery programmes, focused on advanced or progressing disease feed forward into translational studies. Our clinical studies are focused on testing novel agents accompanied by laboratory investigation of biopies to determine the effects on prostate cancer. The rapidly developing genetic epidemiology group is carrying out studies which aim to identify high risk groups and potentially modifiable environmental agents. There is active management, regular workshops and meetings to ensure that the potential added value of the collaborative is realised.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1939227</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Northern Institute for Cancer Research Newcastle</gtr:department><gtr:description>ERK5</gtr:description><gtr:id>DBD7399B-96DD-4BA3-9EEA-5E321BECDBD8</gtr:id><gtr:impact>See Darby et al, 2009</gtr:impact><gtr:outcomeId>8EAA57193CE-1</gtr:outcomeId><gtr:piContribution>ERK5 project - Newcastle University Drug Development Group and Cancer Research Technology - ongoing drug development programme. Added value - post-doctoral researcher from CRT to develop biologic markers downstream of ERK5. PhD student from Newcastle CR UK drug development programme to work on ERK5 targetting molecules.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Public Health and Primary Care</gtr:department><gtr:description>GWS</gtr:description><gtr:id>C4C2C1B6-FB59-40D4-ACDE-670CD176F464</gtr:id><gtr:impact>See previous papers: Eeles et al, 2008; 2009; Ghoussaini et al 2008 and Al Olami et al 2009.</gtr:impact><gtr:outcomeId>87A56415324-1</gtr:outcomeId><gtr:partnerContribution>We also have an exciting collaboration with Professor Ros Eeles at the Institute of Cancer Research, Professor Doug Easton at the Strangeways Laboratory and Professor Paul Pharaoh and Dr Nora Pashayan carrying out studies of genome wide scanning in prostate cancer. Using the bio-repository which has been partly funded by ProMPT this has led to the discovery of a large number of novel pre-disposition alleles and has led to four major publications - three in Nature Genetics and one in the JNCI. The ProMPT collaborative itself continues with its internal collaborations and these include joint clinical studies between Bristol, Sheffield (now Oxford) and Cambridge coupled with a well annotated bio-repository from ProtecT. The bio materials are kept in Oxford and Cambridge and the database is managed through a large clinical trial database in Bristol.</gtr:partnerContribution><gtr:piContribution>We also have an exciting collaboration with Professor Ros Eeles at the Institute of Cancer Research, Professor Doug Easton at the Strangeways Laboratory and Professor Paul Pharaoh and Dr Nora Pashayan carrying out studies of genome wide scanning in prostate cancer. Using the bio-repository which has been partly funded by ProMPT this has led to the discovery of a large number of novel pre-disposition alleles and has led to four major publications - three in Nature Genetics and one in the JNCI. The ProMPT collaborative itself continues with its internal collaborations and these include joint clinical studies between Bristol, Sheffield (now Oxford) and Cambridge coupled with a well annotated bio-repository from ProtecT. The bio materials are kept in Oxford and Cambridge and the database is managed through a large clinical trial database in Bristol.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GWS</gtr:description><gtr:id>4A855EF6-8627-46DB-B843-E4BC5379B455</gtr:id><gtr:impact>See publications: Eeles et al, 2008 and 2009; Al Olami et al 2009; and Ghoussaini et al 2008; 3 Nature Genetics and 1 JNCI paper</gtr:impact><gtr:outcomeId>99EF87830C4-1</gtr:outcomeId><gtr:partnerContribution>We also have an exciting collaboration with Professor Ros Eeles at the Institute of Cancer Research, Professor Doug Easton at the Strangeways Laboratory and Professor Paul Pharaoh and Dr Nora Pashayan carrying out studies of genome wide scanning in prostate cancer. Using the bio-repository which has been partly funded by ProMPT this has led to the discovery of a large number of novel pre-disposition alleles and has led to four major publications - three in Nature Genetics and one in the JNCI. The ProMPT collaborative itself continues with its internal collaborations and these include joint clinical studies between Bristol, Sheffield (now Oxford) and Cambridge coupled with a well annotated bio-repository from ProtecT. The bio materials are kept in Oxford and Cambridge and the database is managed through a large clinical trial database in Bristol.</gtr:partnerContribution><gtr:piContribution>We also have an exciting collaboration with Professor Ros Eeles at the Institute of Cancer Research, Professor Doug Easton at the Strangeways Laboratory and Professor Paul Pharaoh and Dr Nora Pashayan carrying out studies of genome wide scanning in prostate cancer. Using the bio-repository which has been partly funded by ProMPT this has led to the discovery of a large number of novel pre-disposition alleles and has led to four major publications - three in Nature Genetics and one in the JNCI. The ProMPT collaborative itself continues with its internal collaborations and these include joint clinical studies between Bristol, Sheffield (now Oxford) and Cambridge coupled with a well annotated bio-repository from ProtecT. The bio materials are kept in Oxford and Cambridge and the database is managed through a large clinical trial database in Bristol.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Memorial Sloan Kettering Cancer Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Bone turnover and PSA Isoforms</gtr:description><gtr:id>0923ABDA-C1DB-4849-9A15-04E932BA2F03</gtr:id><gtr:impact>Output: MD Thesis (Mr Joshua Philips - viva on 10 Dec 2009), paper in preparation.</gtr:impact><gtr:outcomeId>F481B7708B0-1</gtr:outcomeId><gtr:piContribution>Collaboration with Roche Diagnostics (Dr Nicholas Hoyle, Penzberg, Germany), and Memorial Sloan Kettering Cancer Centre (Dr Hans Lilja, New York, USA) to evaluate markers of bone turnover and PSA isoforms in predicting disease progression and metastases in prostate cancer. Output: MD Thesis (Mr Joshua Philips - viva on 10 Dec 2009), paper in preparation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Roche Diagnostics</gtr:department><gtr:description>Bone turnover and PSA Isoforms</gtr:description><gtr:id>E3E909B2-29FA-4D6D-A815-1969687ECB9A</gtr:id><gtr:impact>Output: MD Thesis (Mr Joshua Philips - viva on 10 Dec 2009), paper in preparation.</gtr:impact><gtr:outcomeId>48CB805B848-1</gtr:outcomeId><gtr:piContribution>Collaboration with Roche Diagnostics (Dr Nicholas Hoyle, Penzberg, Germany), and Memorial Sloan Kettering Cancer Centre (Dr Hans Lilja, New York, USA) to evaluate markers of bone turnover and PSA isoforms in predicting disease progression and metastases in prostate cancer. Output: MD Thesis (Mr Joshua Philips - viva on 10 Dec 2009), paper in preparation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National University of Singapore</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:description>Sprouty2</gtr:description><gtr:id>FD884C0E-02DF-4F88-A35F-552296906C25</gtr:id><gtr:impact>see Darby et al 2009</gtr:impact><gtr:outcomeId>4B2CCC81E82-1</gtr:outcomeId><gtr:piContribution>Sprouty2 - collaboration with Professor Graeme Guy, Singapore</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cambridge - videos of operative procedures</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>BBA0B062-1BBC-4F35-94E4-66F7516929B9</gtr:id><gtr:impact>A number of videos have been made of operative procedures for men with prostate cancer and these have led to features in national newspapers including the Times with a website download of operations being carried out.

videos on BBC and Times websites</gtr:impact><gtr:outcomeId>6F2B0E26BC1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester - various lectures</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>29F1FED1-E0E6-4ADE-8329-4DF31044CA8F</gtr:id><gtr:impact>British Urological Group 2008: Influence of NICE Guidance on Prostate Cancer in the UK 2009: Prostate Cancer Screening British Association of Urological Surgeons 2008: Influence of NICE Guidance on Prostate Cancer in the UK 2009: Use and Timing of Androgen Deprivation in Prostate Cancer British Association of Urological Nurses 2008 The management of hormone refractory prostate cancer Royal College of Physicians 2008 Emerging trends in Urological Oncology Royal College of Physicians London Uro-Oncology Update 2009 The use of 5a Reductase Inhibitors in prostate cancer prevention European Society of Oncological Urology Berlin 2008: Use of Molecular Biomarkers in Prostate Cancer What does PSA failure after radiation or surgery mean European Association of Urology Annual Congress Milan 2008 Pathophysiology of Bone Metastasis in Prostate Cancer European Association of Urology Annual Congress Stockholm 2009 GnRH Antagonists and Hormone Manipulation in Prostate Cancer European Multi-Disciplinary Meeting on Urological Cancer Barcelona 2009 RANK Ligand Inhibition in Prostate Cancer Nikei University Tokyo 2008 Mechanisms of metastatic spread in prostate cancer Japanese Association of Urology 2009 The European Association of Urology Lecture: The Management of Castrate Resistant Prostate Cancer Belgian Association of Urology 2009 RANK Ligand Inhibitors in the management of Metastatic Bone Disease from Prostate Cancer Spanish National Urology Course Institut Juan Puigvert 2009 Isolation and Characterisation of Prostate cancer stem cells using Hoescht 33342 extraction Novel imaging in Prostate Cancer Malmo University 2008 Mechanisms of metastatic spread in prostate cancer Prostate Cancer Support Federation 2009 What is the Importance of Research in Prostate Cancer ? Prostate Cancer UK 2008 The management of advanced prostate cancer The Royal College of Radiologists 2008 Does the surgeon need more or less radiology

n/a</gtr:impact><gtr:outcomeId>6D52D6F2483</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cambridge - various presentations to patients organisations and schools</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>F0181B9D-8693-4978-914F-7D8029D534D7</gtr:id><gtr:impact>A number of presentations and publications have been made together with presentations at Department of Health meetings and NCRI meetings where there are non-academic audiences. In particular, these included a number of new interviews with national papers carried out by Professor Neal and visits to the House of Commons to talk to various scientific committees in connection with prostate translational research. One of these was organised by Cancer Research UK at which Professor Colin Cooper, Professor David Neal spoke to MPs and others in the House of Commons.

n/a</gtr:impact><gtr:outcomeId>B9BECA0FCA2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York - Regular presentations</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>B76AA164-D5E5-4CFE-88E6-63BB3AFC9A7A</gtr:id><gtr:impact>Regular presentations (using and quoting the NCRI badge) to charity collectors, prostate cancer patient support groups and University of the Third Age . Talks not only in York but in Merseyside, Hull, Leeds and London (Royal Society of Medicine).

n/a</gtr:impact><gtr:outcomeId>800B1FEEFFA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle - NICR Outreach</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>06B8F874-5845-405E-B153-4B47F869F908</gtr:id><gtr:impact>The NICR has a full-time local engagement and development (LEAD) manager funded by CR UK and we operate both outreach (to schools and the local community) and invite members of the public to regular open days in our Institute. Presentations from the Principal investigators include talks at local schools, to teachers and to several organised charity events.

n/a</gtr:impact><gtr:outcomeId>AEBC61120EA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow - Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>37B6A86E-AF02-42B5-AE14-C940F3F46E34</gtr:id><gtr:impact>Speaking to open day at the Cancer Research UK Beatson Institute for Cancer Research.

n/a</gtr:impact><gtr:outcomeId>6DBCAF72C8D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York - Laboratory Open Evenings</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>A72DF092-732C-477E-B9A1-3CE87B75ACE4</gtr:id><gtr:impact>At least 3 laboratory open evenings per year when either 3-4 graduate students or younger postdocs give 15 minute talks and a conducted tour of our facilities.

n/a</gtr:impact><gtr:outcomeId>0D5D127FEFB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>13700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>Cambridge/Bristol/Oxford - NIHR, HTA, ProtecT</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>ADC78E63-008E-453F-8AE4-234306EA5BBC</gtr:id><gtr:outcomeId>cppiNCCzx8M0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Programme Grant (Translational Research in Prostate Cancer)</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>4CD00651-E529-4415-B330-765B12EA94A9</gtr:id><gtr:outcomeId>DB3841A34AE0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>349672</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AstraZeneca (Endothelin-1 and Statin Blockade of Prostate Bone Metastasis)</gtr:description><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>1C3855B4-75CC-4FD6-8448-15D848DCB24D</gtr:id><gtr:outcomeId>64239DFEE120</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>158493</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Christie Hospital Research Endowments, Study of Metastatic and cancer stem cell behaviour in prostate and renal cancer</gtr:description><gtr:fundingOrg>Christie Hospital Research Endowments</gtr:fundingOrg><gtr:id>9F70FBFC-04F4-4CE6-A730-0AEC0D932304</gtr:id><gtr:outcomeId>8EF0C03CC740</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>188564</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge - CANCURE (2m euros across 11 participants)</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>D2C99182-D5E6-44E0-B3C3-1E4AFF268E99</gtr:id><gtr:outcomeId>MUiSTvABUxY0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>525098</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cambridge - CRUK TRICC</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>C788A5A7-C945-4E4C-A2DE-DE56030C0EED</gtr:id><gtr:outcomeId>pZpafv2GCuA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>147971</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Association of factors in the folate metabolic pathway with prostate cancer incidence and progression</gtr:description><gtr:fundingOrg>World Cancer Research Fund</gtr:fundingOrg><gtr:fundingRef>2006/15</gtr:fundingRef><gtr:id>BBCC0C20-51DB-42C0-A273-733020C5209A</gtr:id><gtr:outcomeId>E7D3BE798590</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (A Whole Genome association study to identify common susceptibiltiy alleles for prostate cancer)</gtr:description><gtr:end>2009-11-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>852991BE-ED30-4CC0-BA29-616A8A022FF5</gtr:id><gtr:outcomeId>E17C1A37D450</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53782</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Graduate Training Fellowship in Cancer Public Health and Epidemiology</gtr:description><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>32CD60EF-F738-433D-B053-55143A8915B2</gtr:id><gtr:outcomeId>A17D219BC510</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>187000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Philips</gtr:department><gtr:description>Biomarker discovery using proteomic approaches in urological tumours</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Koninklijke Philips Electronics N.V.</gtr:fundingOrg><gtr:id>999A5F71-F7D3-461F-B06E-1E292A18BE9C</gtr:id><gtr:outcomeId>12E05AEFC310</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2007-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>424054</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (The IGF system in prostate cancer aetiology and prognosis a large population based cohort study)</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>30F1A5D3-CF4D-45DB-A419-6626C0785BA7</gtr:id><gtr:outcomeId>704DA9805840</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40071</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUk funding (The feasibility of a randomised controlled trial of dietary interventions for men at high risk of prostate cancer)</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C11046/A10052</gtr:fundingRef><gtr:id>DEDE6CE6-D75C-4E5C-936C-159080754879</gtr:id><gtr:outcomeId>D80F4179EC60</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>74974</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Anthropometric markers of childhood nutrician and cancer</gtr:description><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>E5EC9859-5A86-4123-9D16-55C60ED70C00</gtr:id><gtr:outcomeId>83B1FB55D160</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Effects of Proneural Transcription Factors in Hormone Refractory Disease</gtr:description><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>EDD2AEFB-7C3C-48ED-BE00-7F718801E669</gtr:id><gtr:outcomeId>F0B9989AFC50</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>26000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novel proteomic approach combined with an RNAi screen to identify AR co factors</gtr:description><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>D1C487A2-44BA-4BFD-B925-53D83A759B2A</gtr:id><gtr:outcomeId>8A1422230CF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>149367</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Association of circulating vitamin D metabolite levels with incidence and progression of screen detected prosate cancer</gtr:description><gtr:fundingOrg>World Cancer Research Fund</gtr:fundingOrg><gtr:fundingRef>2007/07</gtr:fundingRef><gtr:id>3A16E445-C486-43CE-898C-7F4AA76B6966</gtr:id><gtr:outcomeId>2B4BFC1EF5F0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4985</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bristol University Cancer Research Committee (Identification of a role for Adipokines in prostate cancer progression)</gtr:description><gtr:fundingOrg>University of Bristol</gtr:fundingOrg><gtr:id>356CBF12-2C2F-4F04-9B15-6C77BDA356DB</gtr:id><gtr:outcomeId>9EA04BB2FCD0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>406500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sheffield - ProsPER Prostate cancer: profiling and evaluation of ncRNA (3m euros across 8 participants)</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>01C99E49-40B7-4D2C-83CD-9B6F541A4EF8</gtr:id><gtr:outcomeId>CB5A3E4457D0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PROMARK Genetic prostate cancer variants as biomarkers of disease progression (2.7m euros across 6 participants)</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>D45B1F0E-2C08-4E6A-8A36-98769F597585</gtr:id><gtr:outcomeId>67EB32C4B8D0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>157000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Equipment grant for a Varian 670-IR spectrometer coupled to a Varian 620-IR Scope</gtr:description><gtr:fundingOrg>Age UK</gtr:fundingOrg><gtr:id>3EC11E63-90D7-4C4C-AB9D-33C611F00EC3</gtr:id><gtr:outcomeId>45F5BC40C680</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Lipid signalling in site directed prostate cancer metastasis. Faculty of Medical and Human Sciences - 2007 School of Medicine Strategic PhD Studentship</gtr:description><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>95D08484-823B-4A93-ABD6-739B9271EB0C</gtr:id><gtr:outcomeId>CC4F71C512C0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Manchester - Noel Clarke - Chair NCRI Prostate CSG 03-09</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>166C4B45-1BB5-4F0D-A71B-0BDC8ECAA50B</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>B0AC1708AAA</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Manchester - Noel Clarke - Scientific Advisor Prostate UK</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>85877FDC-350B-4C2A-87D0-F7B313CE262C</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>3B7586150E0</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>York - Norman Maitland - MRC College of Experts</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>077EB611-494C-4A5B-ABE5-89FCCC40B4FD</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>236B688F8C8</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Steering Committee for Prostate Cancer</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>09EB1B9B-D04B-4717-98EC-E3E7B3B4A81B</gtr:id><gtr:impact>Members of ProMPT continue to have major impact on national policy. Professor Hamdy and Professor Donovan sit on the National Steering Committee for Prostate Cancer.</gtr:impact><gtr:outcomeId>02DCCAC6CCE</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Oxford - Freddie Hamdy - NICE Guidelines</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>BC84A419-C7B1-4F63-81F0-84912A74C8F9</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>5B50F027774</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Manchester - Noel Clarke - Member of Dept of Health Prostate Cancer Advisory Board</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>3E96E010-E877-4AB4-94AA-EB88F75C7F20</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>AC2732A2E78</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>prostate cancer advisory group</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>EC42283F-9BB7-4951-AB0F-11B64A96CBA4</gtr:id><gtr:impact>several policy documents from DoH inluding brachytherapy policy</gtr:impact><gtr:outcomeId>E06E110F675</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Manchester - Noel Clarke - Chair EORTC GU Group Prostate DOG</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>399A4BDD-3844-4141-8456-64239A1F04D7</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>5810AA74CD8</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Manchester - Noel Clarke - Member of Scientific Advisory Board Prostate Cancer Charity</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>0EF983CD-F8A7-41F9-81DE-87CA0C2CCE56</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>AB6A238F7A9</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ProtecT Study</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>2EA8B7E5-EFC1-45D8-B4D7-CDEF2E1B069E</gtr:id><gtr:impact>The ProtecT Study will determine NHS policy when it is published after 2015.</gtr:impact><gtr:outcomeId>1D141AB1564</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Prostate Cancer Action Group of the Dept of Health</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>61F426F8-9662-4E8B-B32C-AC943D8D18ED</gtr:id><gtr:impact>Professor Neal and Professor Cooper from the ICR sit on Prostate Cancer Action Group of the Dept of Health and Professor Neal has recently been appointed to be Vice Chair of the Prostate Cancer Action Group working with Dr Mike Richards.</gtr:impact><gtr:outcomeId>DACB726CE88</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Manchester - Noel Clarke - Advisor HTA/NICE</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>3600C51C-2D7D-44BC-90BB-B43A6EFB3310</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>9BB31C441DC</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>A successful ERK5 project will delivery a clinical candidate in 2-3 years.</gtr:description><gtr:id>E835AAD2-3FDB-4C77-9C24-620A80B654D3</gtr:id><gtr:impact>see 9.6</gtr:impact><gtr:outcomeId>80524024DD6</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ERK5</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We are developing mouse monoclonal phospho-p68 antibodies to detect activated p68 in clinical material. These antibodies may be more useful than the commercially available p68 antibodies to detect changes in prostate cancer patients with disease progression.</gtr:description><gtr:id>F0FB58BA-1D61-4C2E-966C-D5F49307F941</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>1F800248B31</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>phospho-p68 antibodies</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The major aim of our NCRI funded research was to (i) increase the pool of prostate cancer stem cell cultures available for molecular analyses and (ii) to optimise xenografting conditions for prostate tissues and stem cell derived cultures. More than 50 cancer cultures have been established and banked. It is clear that these cultures change with time in culture and the availability of larger numbers of truly primary cultures from human material which share the phenotype with the original tissues, for example by expression of the TMPRSS2-ERG fusion (which is lost on prolonged culture). Optimised xenografting conditions remain difficult to achieve. However we now have 4 serially passaged xenografts from which stem cells can be retrieved. One culture has been passages 19 times in vivo. A unique feature of this resource is the frequency and location of the observed metastases from a renal capsule or even a subcutaneous implant.</gtr:description><gtr:id>2096DAEA-49F3-4C63-B32D-DB4BA013016A</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>E5729E9A15F</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>York - 50 Cancer cultures established and banked</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>As an extension of the previous grant we have now expanded and published in public data bases an annotated catalogue of genes (based on the Affymetrix plus 2 human chip) expressed in various differentiated cell types in prostate and prostate cancer (Arrayexpress).</gtr:description><gtr:id>168C88C6-CD41-41D3-89C8-3D9CF2CF811E</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>FD8270B7968</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>York - annotated catalogue of genes</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Chemometric (FTIR) Grading and Staging of Prostatic Tissue</gtr:description><gtr:id>C670507E-B849-45BD-A6CA-E759991C20CE</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>CD75F104EEC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Chemometric (FTIR) Grading and Staging of Prostatic Tissue</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Databases have been established for ProMPT (Dr Rajeev Kumar Sheffield/Oxford) for annotated clinical samples.</gtr:description><gtr:id>41AFB72D-6A67-4CA5-9902-87E9BB364D08</gtr:id><gtr:impact>ONGOING PUBLICATIONS AS IN PUBLICATION LIST</gtr:impact><gtr:outcomeId>A13A034E0D4</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ProMPT</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>1. Bone Marrow Stroma co-culture models of a. Transendothelial migration b. Invasion c. Metastatic colony formation d. Chemotherapeutic intervention</gtr:description><gtr:id>DFD9C4AF-733E-48F0-B05E-FE4784D81F41</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>7E08A48013A</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Bone Marrow Stroma co-culture models</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Databases have been established for the clinical trail (ProtecT).</gtr:description><gtr:id>CD05F913-AD66-4F48-9582-1F5768977400</gtr:id><gtr:impact>several high impact publications as outlined in publications</gtr:impact><gtr:outcomeId>B1495BFB95C</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ProtecT Database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new joint database has been established between Professor Cooper and Professor Neal and Professor Hamdy in Oxford to deal with the large amount of scientific data that is now coming through from Human bio materials.</gtr:description><gtr:id>9C691BC4-85B1-4EBE-A655-CF4D2E6CBB5F</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>54A7139F538</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>New joint ProMPT/Southern Collaborative Database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Plasmids created within this project have been made freely available to the research community. Multiple requests have been made from international research groups and products shipped as required.</gtr:description><gtr:id>BBBB6CD3-78B8-43F5-9452-0C2D2EEC0FF0</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>76B60ED6F72</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Newcastle - Plasmids</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>3. Tissue/Serum Bank a. Snap Frozen Tissue b. FFPE Tissue c. Single Cell Suspensions d. Epithelial e. Fibroblast f. Serum</gtr:description><gtr:id>5244501A-F177-4F3C-8054-B66ACA4E98BC</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>E26E95250F7</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Tissue/Serum Bank</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Methods of carrying out chromatine immunoprecipitation in prostate cells have now been published and a paper has been prepared doing the same for chromatine immunoprecipitation and high through put sequencing which is ready to go as a paper for androgen receptor function.</gtr:description><gtr:id>D77AB70A-E489-404F-A074-F067618F446C</gtr:id><gtr:impact>SEE PAPERS BY MASSIE AND MILLS</gtr:impact><gtr:outcomeId>8AE5A515C1B</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Chromatin immunoprecipitation methods</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>ProMPT and ProtecT biorespoitories, design and development of standard operating procedures for biobanking (attached), establishment of a processing facility using automated equipment at Oxford.</gtr:description><gtr:id>3FC1DE1C-CC26-4B75-999A-F42D2DA9022C</gtr:id><gtr:impact>MANY PAPERS AS IN PUBLICATIONS LIST</gtr:impact><gtr:outcomeId>50C3E1822B7</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ProMPT and ProtecT bio-repository</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>2. Isolation of prostatic epithelial side populations (SP) from benign and malignant human tissue</gtr:description><gtr:id>5D8ADDA7-2A56-45EB-B2D2-86F48F476A21</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>7CFB05379C5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Isolation of prostatic epithelial side populations (SP)</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>5. Affymetrix mirco-array database of prostatic SP subpopulations from normal, benign and malignant human tissue</gtr:description><gtr:id>254F9F19-3435-4485-A2D5-AA5E30DB5E35</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>F2FE9EA4FFD</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Affymetrix database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Pro-Cure Therapeutics Ltd</gtr:companyName><gtr:description>Pro-Cure Therapeutics has now raised around &amp;pound;3M over the last 4 years, and most recently a final seed round of &amp;pound;700,000 in the last month. It has 10 scientists and a small admin and marketing staff. ; http://www.pro-cure.uk.com/</gtr:description><gtr:id>2F7C4318-1267-422B-B4EC-1433A98B0093</gtr:id><gtr:impact>Negotiation for alliances with major Pharma companies in the Stem cell field are at an advanced stage, and bids for large scale VC funding for preclinical and clinical studies have passed an initial due diligence. Two research collaborations with International Pharma have already been completed.</gtr:impact><gtr:outcomeId>51F8F6865F8</gtr:outcomeId><gtr:url>http://www.pro-cure.uk.com/</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>B75CF71F-C47B-4A50-B927-5C580523B0B6</gtr:id><gtr:title>STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>CF39428F0DE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AC9B3A8-769C-4741-BB4F-C6A12D81727D</gtr:id><gtr:title>Measurement of elastic properties of prostate cancer cells using AFM.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9138cc62fb6ba0cbdcd13f43656be55"><gtr:id>a9138cc62fb6ba0cbdcd13f43656be55</gtr:id><gtr:otherNames>Faria EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>1B55CA54897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A05A986-AB4B-4C9F-8C06-F0F4C318D726</gtr:id><gtr:title>Targeting alternative splicing in prostate oncology.</gtr:title><gtr:parentPublicationTitle>Discovery medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7208eb46679b472c9f0252903acf90fd"><gtr:id>7208eb46679b472c9f0252903acf90fd</gtr:id><gtr:otherNames>Carling PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1539-6509</gtr:issn><gtr:outcomeId>1A1005BA1B4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A4A0D79-FF59-4056-A045-2A739A6C9C7E</gtr:id><gtr:title>The association of atopic diseases with breast, prostate, and colorectal cancers: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76e8eaa621b4cdcd8521cf5819ce30e5"><gtr:id>76e8eaa621b4cdcd8521cf5819ce30e5</gtr:id><gtr:otherNames>Vojtechova P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn><gtr:outcomeId>B451481233B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CB0F164-052F-4040-BCB5-E84171AA5C76</gtr:id><gtr:title>A role for neurotensin in bicalutamide resistant prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83def28597e149afa1b36bc96fab97b3"><gtr:id>83def28597e149afa1b36bc96fab97b3</gtr:id><gtr:otherNames>Vias M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>EBAB256A098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA525068-C131-4123-BD29-941E3517DCD9</gtr:id><gtr:title>Factors influencing the discrimination and classification of prostate cancer cell lines by FTIR microspectroscopy.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c0f8c8d917ac80eaae4d51f5cc28c1e"><gtr:id>9c0f8c8d917ac80eaae4d51f5cc28c1e</gtr:id><gtr:otherNames>Harvey TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>124EFFA3A5C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9FA4E26-3C96-4618-9149-C66AAF633BFB</gtr:id><gtr:title>Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b77852affe714d068d9d72d35f5a894a"><gtr:id>b77852affe714d068d9d72d35f5a894a</gtr:id><gtr:otherNames>McCracken SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>725D84F0D2E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DA5D92F-70C4-43F7-A3DF-D9C01E0F5887</gtr:id><gtr:title>Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63f1dd9fac024b84b36c7dcd9baf0863"><gtr:id>63f1dd9fac024b84b36c7dcd9baf0863</gtr:id><gtr:otherNames>Collin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>B4DC40BFC20</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB434104-67F3-47A7-A013-C200D84ED73E</gtr:id><gtr:title>Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Journal of cellular biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2952c102b249168752e2b64fa0e7015b"><gtr:id>2952c102b249168752e2b64fa0e7015b</gtr:id><gtr:otherNames>Cross NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0730-2312</gtr:issn><gtr:outcomeId>55D7DCCB40A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>653F04E5-C5AF-4E30-A203-A9BCCF7AAD5F</gtr:id><gtr:title>iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e79da553f4f5d957a0c70efd742c6829"><gtr:id>e79da553f4f5d957a0c70efd742c6829</gtr:id><gtr:otherNames>Glen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>7001F6BAA99</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD725719-B8A6-4CBA-BCD6-07B193E505F4</gtr:id><gtr:title>Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ed11060a33193423bb1c0164f69792a"><gtr:id>4ed11060a33193423bb1c0164f69792a</gtr:id><gtr:otherNames>Roupr?t M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>B41858C02A3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAC98466-3374-4FC0-86CE-372BC502441D</gtr:id><gtr:title>Prostate cancer stem cells: a new target for therapy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eab58915d98e5a265b7a319493723193"><gtr:id>eab58915d98e5a265b7a319493723193</gtr:id><gtr:otherNames>Maitland NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>97CC55D669C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>506A8D18-0868-4CB3-BCDD-88A15A68066F</gtr:id><gtr:title>Regulation of gene expression by the RNA-binding protein Sam68 in cancer.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/926b354ae4e38e2c054bd1f60c23a749"><gtr:id>926b354ae4e38e2c054bd1f60c23a749</gtr:id><gtr:otherNames>Rajan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>3C82F3A3F30</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EC9B874-97E9-48CD-812E-D7C8E9812F0B</gtr:id><gtr:title>Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a2f8e88b4d5243706965b6284b353bd"><gtr:id>6a2f8e88b4d5243706965b6284b353bd</gtr:id><gtr:otherNames>Hussain S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>2D909D02E3A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F53066C3-C349-40B1-888B-668E4379CEC4</gtr:id><gtr:title>Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02cc3ebad46cdcf3cb47fc523c22e6be"><gtr:id>02cc3ebad46cdcf3cb47fc523c22e6be</gtr:id><gtr:otherNames>Rogerson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>9CA507B99AE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAA49E61-1B40-4DE0-AF2C-29CEE497B548</gtr:id><gtr:title>Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2adbed115a071b1f1279b658b2a51ceb"><gtr:id>2adbed115a071b1f1279b658b2a51ceb</gtr:id><gtr:otherNames>Aitchison AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>985E69A7B03</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A7098A6-DE53-4D65-ADF9-C3BD13E85193</gtr:id><gtr:title>Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>CC0472C651F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>497EF6F8-31DE-489F-8481-1E7488489C17</gtr:id><gtr:title>Terminal and progenitor lineage-survival oncogenes as cancer markers.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83def28597e149afa1b36bc96fab97b3"><gtr:id>83def28597e149afa1b36bc96fab97b3</gtr:id><gtr:otherNames>Vias M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>FE5859B637A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9EB34A5-40FD-483D-9277-FC778A1D3108</gtr:id><gtr:title>ChIPping away at gene regulation.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42f82449a2b9f27ce959a47327c4da62"><gtr:id>42f82449a2b9f27ce959a47327c4da62</gtr:id><gtr:otherNames>Massie CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>75394A5A681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA0DB010-69F0-40E9-82D1-984C052AC3EE</gtr:id><gtr:title>Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63f1dd9fac024b84b36c7dcd9baf0863"><gtr:id>63f1dd9fac024b84b36c7dcd9baf0863</gtr:id><gtr:otherNames>Collin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>8D8A3F9936B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10089394-95F6-4B9F-AC41-FA894867FB59</gtr:id><gtr:title>Identification of new genetic risk factors for prostate cancer.</gtr:title><gtr:parentPublicationTitle>Asian journal of andrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e44cdeab746fb44de905c18382c13553"><gtr:id>e44cdeab746fb44de905c18382c13553</gtr:id><gtr:otherNames>Guy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1008-682X</gtr:issn><gtr:outcomeId>EE8993A5BE8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B19979E-222A-4B70-8713-E25320804E97</gtr:id><gtr:title>Bisphosphonates in hormone-refractory prostate cancer: do we have a toxicity problem?</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5695006f0a14fdaa8b40cc87ee828535"><gtr:id>5695006f0a14fdaa8b40cc87ee828535</gtr:id><gtr:otherNames>Clarke NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>4A6BC3363C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40BEE714-E37F-4BEA-8887-F09AA727A638</gtr:id><gtr:title>Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d69429222c951d3cd766646e75b77d35"><gtr:id>d69429222c951d3cd766646e75b77d35</gtr:id><gtr:otherNames>Gazi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn><gtr:outcomeId>88E0993F33B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73DA7D39-9B68-4844-9819-CD2ADB76CCAC</gtr:id><gtr:title>Structural basis for the nuclear import of the human androgen receptor.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c268711dce5fc15494f301ef61400ad9"><gtr:id>c268711dce5fc15494f301ef61400ad9</gtr:id><gtr:otherNames>Cutress ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>6F6A4FCFA18</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92E227E0-36CC-4FC7-B637-B8C39B531D7A</gtr:id><gtr:title>Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05c37759423ca8ce0e63b42366a856a6"><gtr:id>05c37759423ca8ce0e63b42366a856a6</gtr:id><gtr:otherNames>Berry PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn><gtr:outcomeId>E179CB777C9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6750CA7-92D0-4F79-A9FA-5B01934F7612</gtr:id><gtr:title>Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39142f84dda93520d2d486500d7d5e40"><gtr:id>39142f84dda93520d2d486500d7d5e40</gtr:id><gtr:otherNames>Leiblich A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>EF8CA111013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0909CF32-740B-4F81-AA2E-81101677F09F</gtr:id><gtr:title>Multiple newly identified loci associated with prostate cancer susceptibility.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4e687e7e62db23388559e46d798d39c"><gtr:id>f4e687e7e62db23388559e46d798d39c</gtr:id><gtr:otherNames>Eeles RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>CCC5B7780A9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14DE24A9-A3A8-4D67-815B-A639147EC303</gtr:id><gtr:title>Expression of beta-dystroglycan is reduced or absent in many human carcinomas.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1a5b3b8a37936a5d0b0949a4b7ccd08"><gtr:id>f1a5b3b8a37936a5d0b0949a4b7ccd08</gtr:id><gtr:otherNames>Cross SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>D45E38B8DFF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98433D16-F3DE-4B73-9DA5-B58EED015148</gtr:id><gtr:title>Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a32b45b31a2cdf6d894c4ab0b50a52fd"><gtr:id>a32b45b31a2cdf6d894c4ab0b50a52fd</gtr:id><gtr:otherNames>Kote-Jarai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>doi_55f983983b2d1c6f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E3BCCC9-2D05-44AD-B7EE-11146EBE9A73</gtr:id><gtr:title>Imaging the effects of castration on bone turnover and hormone-independent prostate cancer colonization of bone.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2952c102b249168752e2b64fa0e7015b"><gtr:id>2952c102b249168752e2b64fa0e7015b</gtr:id><gtr:otherNames>Cross NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>0D2E4D0785B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB597C08-0C99-41A0-B07B-C18B021429A7</gtr:id><gtr:title>Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f69551d9c96ceb037d387cf751a53042"><gtr:id>f69551d9c96ceb037d387cf751a53042</gtr:id><gtr:otherNames>Darby S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>570F465C3EB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4F8B03D-C1CE-46AB-8299-B46C8914329C</gtr:id><gtr:title>Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9077fd9389eec4be3885d190da43c481"><gtr:id>9077fd9389eec4be3885d190da43c481</gtr:id><gtr:otherNames>Sutcliffe P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>0F95C4E53E4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>501725A5-B90F-428C-9F83-674D47BCF74A</gtr:id><gtr:title>Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4a9a3f8c09bdee7e2525738a05bed1d"><gtr:id>e4a9a3f8c09bdee7e2525738a05bed1d</gtr:id><gtr:otherNames>Batra J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15351_21_22132073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F76AD3F-31DC-45F6-A9AB-AAAF35C96940</gtr:id><gtr:title>The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/926b354ae4e38e2c054bd1f60c23a749"><gtr:id>926b354ae4e38e2c054bd1f60c23a749</gtr:id><gtr:otherNames>Rajan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>3DCC580BFE8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A112FB3-464A-4A33-A160-E1FB44907B32</gtr:id><gtr:title>DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5cee686a0ea012b21ea60eb22d8339d"><gtr:id>b5cee686a0ea012b21ea60eb22d8339d</gtr:id><gtr:otherNames>Rehman I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>D7C9F042803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9053722A-3961-476F-B269-2724DEC8EBCF</gtr:id><gtr:title>Proteomic identification of heterogeneous nuclear ribonucleoprotein L as a novel component of SLM/Sam68 Nuclear Bodies.</gtr:title><gtr:parentPublicationTitle>BMC cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/926b354ae4e38e2c054bd1f60c23a749"><gtr:id>926b354ae4e38e2c054bd1f60c23a749</gtr:id><gtr:otherNames>Rajan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2121</gtr:issn><gtr:outcomeId>5C0665112ED</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>893187C0-646A-43C2-A41F-47C9D8476B32</gtr:id><gtr:title>Shared common variants in prostate cancer and blood lipids.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b6e173432c4fadd79de8666f791978f"><gtr:id>7b6e173432c4fadd79de8666f791978f</gtr:id><gtr:otherNames>Andreassen OA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>doi_55f983983b2351a6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02F6D410-9D70-474D-8E0A-E3E9AB725302</gtr:id><gtr:title>Reflection contributions to the dispersion artefact in FTIR spectra of single biological cells.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07e02bedba173c182037b7f6cb557229"><gtr:id>07e02bedba173c182037b7f6cb557229</gtr:id><gtr:otherNames>Bassan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>312222DABC3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AB4B2F5-D5C0-48DA-A903-8797254C5C53</gtr:id><gtr:title>LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23ffe610beb51e50bb1847123bae6ac4"><gtr:id>23ffe610beb51e50bb1847123bae6ac4</gtr:id><gtr:otherNames>Thirkettle HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>D7110958201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FF4C4D1-4A28-4805-8903-F809708C90DE</gtr:id><gtr:title>Expression of GnRH type II is regulated by the androgen receptor in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Endocrine-related cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f69551d9c96ceb037d387cf751a53042"><gtr:id>f69551d9c96ceb037d387cf751a53042</gtr:id><gtr:otherNames>Darby S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1351-0088</gtr:issn><gtr:outcomeId>F7F6C468A45</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>028860C0-ABD8-4AC2-8EFC-B0A83C49D864</gtr:id><gtr:title>BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f69551d9c96ceb037d387cf751a53042"><gtr:id>f69551d9c96ceb037d387cf751a53042</gtr:id><gtr:otherNames>Darby S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>AAE9C43D58D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51645EAB-296E-4740-AD0D-07DC0461C673</gtr:id><gtr:title>Discrimination of prostate cancer cells and non-malignant cells using secondary ion mass spectrometry.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32bd6acdb52d21bf5f76cc1afe82eb5c"><gtr:id>32bd6acdb52d21bf5f76cc1afe82eb5c</gtr:id><gtr:otherNames>Baker MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>F6DBE75B76C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CA12DEC-2DBB-4C35-8F37-27CEDF0391AA</gtr:id><gtr:title>Phosphorylation of Tat-interactive protein 60 kDa by protein kinase C epsilon is important for its subcellular localisation.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31c6b20d635113b9ee2f330171e4394f"><gtr:id>31c6b20d635113b9ee2f330171e4394f</gtr:id><gtr:otherNames>Sapountzi V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn><gtr:outcomeId>0E98BF7F6EF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80556097-618D-4FFD-A565-E2E5A3A48AA8</gtr:id><gtr:title>Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35c6991ce99ad3566a0d54e6cd5a6066"><gtr:id>35c6991ce99ad3566a0d54e6cd5a6066</gtr:id><gtr:otherNames>Sahadevan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>1695C33A6D0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>097D93C6-CD2E-4927-932B-47A06A5E9B06</gtr:id><gtr:title>Blood pressure and risk of prostate cancer: Cohort Norway (CONOR).</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc85d919b02f151621e30efefab2e6b6"><gtr:id>cc85d919b02f151621e30efefab2e6b6</gtr:id><gtr:otherNames>Martin RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn><gtr:outcomeId>2F5FA33FEC3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35D931BA-BFDB-49AF-97D9-D66E4C70A689</gtr:id><gtr:title>Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/465cedd023e5b9ab10b8ae7e99b320ec"><gtr:id>465cedd023e5b9ab10b8ae7e99b320ec</gtr:id><gtr:otherNames>Sharrard RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>9CBAE6B045C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2399BE62-72A0-4E69-842A-29CE81EE8C8F</gtr:id><gtr:title>Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d61a8e019181cfb919b7ee6f4053188"><gtr:id>4d61a8e019181cfb919b7ee6f4053188</gtr:id><gtr:otherNames>Metcalfe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>866A7A7AC0F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B983D1E1-C4E3-42CB-B067-EF2D674CA8EC</gtr:id><gtr:title>Advances in mouse models of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Expert reviews in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ca0f5e385ea7be4f8f9a44484558586"><gtr:id>5ca0f5e385ea7be4f8f9a44484558586</gtr:id><gtr:otherNames>Ahmad I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1462-3994</gtr:issn><gtr:outcomeId>325B8684CF7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5D80055-B414-4DD2-BF2B-E270479E519F</gtr:id><gtr:title>SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5af7f3a7fe061d49481855fb8c93beab"><gtr:id>5af7f3a7fe061d49481855fb8c93beab</gtr:id><gtr:otherNames>Tatarov O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>31BB7165BFB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F3CD7BE-8F2A-45C8-8068-FA6DAFC87FBB</gtr:id><gtr:title>Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e14f6924e8f2de2ef38ea52a993768cd"><gtr:id>e14f6924e8f2de2ef38ea52a993768cd</gtr:id><gtr:otherNames>Pashayan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>70CFA76DDE3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF187D4B-C87E-4DBE-98F3-E4C536627FED</gtr:id><gtr:title>Multiple loci with different cancer specificities within the 8q24 gene desert.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71e2ebd1f2b2b3fb1e5851e7c43fcdba"><gtr:id>71e2ebd1f2b2b3fb1e5851e7c43fcdba</gtr:id><gtr:otherNames>Ghoussaini M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>CAF85743DE0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4F27763-5CA2-40EA-885D-6CFB8B9B7C18</gtr:id><gtr:title>A FTIR microspectroscopic study of the uptake and metabolism of isotopically labelled fatty acids by metastatic prostate cancer</gtr:title><gtr:parentPublicationTitle>Vibrational Spectroscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d69429222c951d3cd766646e75b77d35"><gtr:id>d69429222c951d3cd766646e75b77d35</gtr:id><gtr:otherNames>Gazi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>209792B9038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D7E23F1-B200-4779-90AA-62C9C86BE871</gtr:id><gtr:title>Classification of fixed urological cells using Raman tweezers.</gtr:title><gtr:parentPublicationTitle>Journal of biophotonics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c0f8c8d917ac80eaae4d51f5cc28c1e"><gtr:id>9c0f8c8d917ac80eaae4d51f5cc28c1e</gtr:id><gtr:otherNames>Harvey TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1864-063X</gtr:issn><gtr:outcomeId>F2640E892B9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94F8BCE5-F028-424B-9B5E-1DA0BFBDD40B</gtr:id><gtr:title>Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ba6cad88ac200722f89e1a5844f7bb"><gtr:id>93ba6cad88ac200722f89e1a5844f7bb</gtr:id><gtr:otherNames>Roddam AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>0C06B480E02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57C983FC-03B1-4319-8B1E-55C0486CA445</gtr:id><gtr:title>RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1548ef1eeca4227f26890d1c66707f1"><gtr:id>d1548ef1eeca4227f26890d1c66707f1</gtr:id><gtr:otherNames>Aitchison A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>A91B0304636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38FB46D2-A227-4436-9735-7BF715EEC18C</gtr:id><gtr:title>Investigating FTIR based histopathology for the diagnosis of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of biophotonics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32bd6acdb52d21bf5f76cc1afe82eb5c"><gtr:id>32bd6acdb52d21bf5f76cc1afe82eb5c</gtr:id><gtr:otherNames>Baker MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1864-063X</gtr:issn><gtr:outcomeId>E172F0CBD36</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C0AFB81-4AB4-4077-9000-89B5B3422462</gtr:id><gtr:title>Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c70d8f63de3d1e0f6e91b30969ad3685"><gtr:id>c70d8f63de3d1e0f6e91b30969ad3685</gtr:id><gtr:otherNames>Endogenous Hormones and Prostate Cancer Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>56A4E6A40A9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EC5E3A0-A173-4C90-8436-6B4E55E72AE8</gtr:id><gtr:title>Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b33c969b8b2e6a09cc05cd1b67d2679d"><gtr:id>b33c969b8b2e6a09cc05cd1b67d2679d</gtr:id><gtr:otherNames>Morris MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>25B4E3F8DDE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>497E9EC6-353D-4BB7-AF69-6F5E54414732</gtr:id><gtr:title>The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db8344643f972fa3293eca1318836e28"><gtr:id>db8344643f972fa3293eca1318836e28</gtr:id><gtr:otherNames>Bryant RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>0C4E6038F5E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80F64DF3-8502-4D66-8363-69191D7B8153</gtr:id><gtr:title>Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbfd9fb6e692d07596464ca94848bf67"><gtr:id>fbfd9fb6e692d07596464ca94848bf67</gtr:id><gtr:otherNames>Chen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>FFFCFB5F835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0A9ED2B-14BA-4A0F-AC5E-4C79FE7EB86F</gtr:id><gtr:title>Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.</gtr:title><gtr:parentPublicationTitle>BMC genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb06dba489d63588c60d8eefc1ba1cf1"><gtr:id>cb06dba489d63588c60d8eefc1ba1cf1</gtr:id><gtr:otherNames>Zuber V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2164</gtr:issn><gtr:outcomeId>5a31d73904bcc3.95112670</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79D4B3AD-1217-4CD1-98EE-9F491E934D85</gtr:id><gtr:title>Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f830a256cf28c5d5a9a9781e1d0d8117"><gtr:id>f830a256cf28c5d5a9a9781e1d0d8117</gtr:id><gtr:otherNames>Rowlands MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>4686E8E2928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6B7C33D-74EC-4DB7-B61E-C219726A9E20</gtr:id><gtr:title>A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a32b45b31a2cdf6d894c4ab0b50a52fd"><gtr:id>a32b45b31a2cdf6d894c4ab0b50a52fd</gtr:id><gtr:otherNames>Kote-Jarai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>6E04C9B4567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9D9EA9F-BE37-444F-964E-8CF0ED9EB117</gtr:id><gtr:title>Labeling and identification of LNCaP cell surface proteins: a pilot study.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aebddcb3a950a46dafb6e76a71689277"><gtr:id>aebddcb3a950a46dafb6e76a71689277</gtr:id><gtr:otherNames>Whitaker HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>426625E3B51</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62C7AAF2-386B-45ED-B2A9-0AE00451CBE3</gtr:id><gtr:title>Cd133: a marker of transit amplification rather than stem cell phenotype in the prostate?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d13095fd15ad6517f3f97f79f0bc4b93"><gtr:id>d13095fd15ad6517f3f97f79f0bc4b93</gtr:id><gtr:otherNames>Grey BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>69E4E441BD8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6570DB67-E901-4281-AE72-5F3707D632B2</gtr:id><gtr:title>Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f68a702ef5ec550ca56df961f101e510"><gtr:id>f68a702ef5ec550ca56df961f101e510</gtr:id><gtr:otherNames>Logan IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>C9DFD92605F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BABA4D6-3969-4638-B2BB-686FA8A7C09E</gtr:id><gtr:title>Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0fd046301fb964841ba7c1a991a46c5"><gtr:id>b0fd046301fb964841ba7c1a991a46c5</gtr:id><gtr:otherNames>Rosario DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>3E267E8A95B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEFB333A-B136-4E04-8305-CD7EA6DD2C89</gtr:id><gtr:title>Unlocking the molecular archive: the emerging use of formalin-fixed paraffin-embedded tissue for biomarker research in urological cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72313d0b4fb74aa7f876af123ebcad82"><gtr:id>72313d0b4fb74aa7f876af123ebcad82</gtr:id><gtr:otherNames>Gnanapragasam VJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>4C3BF47DED0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD7855DE-819C-44EA-983B-9FB593C59940</gtr:id><gtr:title>Discrimination of prostate cancer cells by reflection mode FTIR photoacoustic spectroscopy.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c0f8c8d917ac80eaae4d51f5cc28c1e"><gtr:id>9c0f8c8d917ac80eaae4d51f5cc28c1e</gtr:id><gtr:otherNames>Harvey TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>76D285F241D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A0C9D31-6540-439F-81E1-94A9A9C51D99</gtr:id><gtr:title>Nuclear trafficking and functions of endocytic proteins implicated in oncogenesis.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a39d059ab0069ad2703a05b5a31df83f"><gtr:id>a39d059ab0069ad2703a05b5a31df83f</gtr:id><gtr:otherNames>Borlido J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>1D209D89F75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1CFBCB8-7372-45BF-B3C5-D9628EBE326E</gtr:id><gtr:title>Clathrin is spindle-associated but not essential for mitosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a39d059ab0069ad2703a05b5a31df83f"><gtr:id>a39d059ab0069ad2703a05b5a31df83f</gtr:id><gtr:otherNames>Borlido J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>00F1461B15D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C878DA32-E693-4F71-BC4A-33E82BE85ABB</gtr:id><gtr:title>Evaluating genetic risk for prostate cancer among Japanese and Latinos.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e113d45be4cf5ea95a39fd936b506f1"><gtr:id>7e113d45be4cf5ea95a39fd936b506f1</gtr:id><gtr:otherNames>Cheng I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>doi_55f983983b360400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39CFA516-203B-40A8-83EA-9A65A0ED733E</gtr:id><gtr:title>Molecular mechanisms of metastasis in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Asian journal of andrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5695006f0a14fdaa8b40cc87ee828535"><gtr:id>5695006f0a14fdaa8b40cc87ee828535</gtr:id><gtr:otherNames>Clarke NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1008-682X</gtr:issn><gtr:outcomeId>B6CB3AF700E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FF1BB60-4408-4B8F-A5FE-41FB70CE2281</gtr:id><gtr:title>Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdcebffa3bde4cde28943efefbeb46fb"><gtr:id>bdcebffa3bde4cde28943efefbeb46fb</gtr:id><gtr:otherNames>Zuccolo L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>EEFB72067D9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AEF3F03-C1B4-4D1C-87E6-E071FBE815F2</gtr:id><gtr:title>Coupling transcription to RNA processing via the p68 DEAD box RNA helicase androgen receptor co-activator in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b27ff50d0bfaf49d2437a6da8c0342d6"><gtr:id>b27ff50d0bfaf49d2437a6da8c0342d6</gtr:id><gtr:otherNames>Clark EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>39A3A4053FD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DD138F4-059E-491A-BEDB-52418BA6E4FE</gtr:id><gtr:title>Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63f1dd9fac024b84b36c7dcd9baf0863"><gtr:id>63f1dd9fac024b84b36c7dcd9baf0863</gtr:id><gtr:otherNames>Collin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>C4C48A8800B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD97A392-C2E3-4B16-A2EE-E5EAF795D9F1</gtr:id><gtr:title>Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06983d0c4a026f56798867194f0a903c"><gtr:id>06983d0c4a026f56798867194f0a903c</gtr:id><gtr:otherNames>Kershaw LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>71CE6730FDD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0948071C-6028-4441-9F38-972BFFA65BD2</gtr:id><gtr:title>Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway.</gtr:title><gtr:parentPublicationTitle>Cancer causes &amp; control : CCC</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc85d919b02f151621e30efefab2e6b6"><gtr:id>cc85d919b02f151621e30efefab2e6b6</gtr:id><gtr:otherNames>Martin RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0957-5243</gtr:issn><gtr:outcomeId>C58BF115990</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C33AAC2A-8E58-42C6-B956-936330EBD54F</gtr:id><gtr:title>Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd753fda3bce2547bbdf1a5e6b8c20d2"><gtr:id>cd753fda3bce2547bbdf1a5e6b8c20d2</gtr:id><gtr:otherNames>Lane JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>36DCD373261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A48690C0-7526-42CE-AAFF-5DA0EAA70565</gtr:id><gtr:title>Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d00927a64f1f34d88638bf3dd2d3f8c"><gtr:id>7d00927a64f1f34d88638bf3dd2d3f8c</gtr:id><gtr:otherNames>Gusev A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>585d50ea2f53b5.55944199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0BB9578-EE74-4806-B635-8EF8ADFD67B7</gtr:id><gtr:title>Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f68a702ef5ec550ca56df961f101e510"><gtr:id>f68a702ef5ec550ca56df961f101e510</gtr:id><gtr:otherNames>Logan IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5D4FCC61E18</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39064195-93B4-4232-8901-D5A61DA015BD</gtr:id><gtr:title>Pro-neural transcription factors as cancer markers.</gtr:title><gtr:parentPublicationTitle>BMC medical genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83def28597e149afa1b36bc96fab97b3"><gtr:id>83def28597e149afa1b36bc96fab97b3</gtr:id><gtr:otherNames>Vias M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1755-8794</gtr:issn><gtr:outcomeId>0F53435202B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCAE7B64-5B03-4EDB-9FD1-7043A74AF3BE</gtr:id><gtr:title>New androgen receptor genomic targets show an interaction with the ETS1 transcription factor.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42f82449a2b9f27ce959a47327c4da62"><gtr:id>42f82449a2b9f27ce959a47327c4da62</gtr:id><gtr:otherNames>Massie CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>02CC21789C9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0EBB8AD-86E8-4B98-9A60-F8BB2FDF429B</gtr:id><gtr:title>The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e22874ccdbf6480b374e34cbae6d3b42"><gtr:id>e22874ccdbf6480b374e34cbae6d3b42</gtr:id><gtr:otherNames>Waterman EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>C029E948294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E39714CE-17A9-42A9-A95B-BBA03A01A977</gtr:id><gtr:title>FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32bd6acdb52d21bf5f76cc1afe82eb5c"><gtr:id>32bd6acdb52d21bf5f76cc1afe82eb5c</gtr:id><gtr:otherNames>Baker MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>46CB8EE8B82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A70F30C9-080A-4751-9D73-575E761EB5A4</gtr:id><gtr:title>Optical artefacts in transflection mode FTIR microspectroscopic images of single cells on a biological support: the effect of back-scattering into collection optics.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f3b0d1be17ddd4dddfaf7d483017db4"><gtr:id>6f3b0d1be17ddd4dddfaf7d483017db4</gtr:id><gtr:otherNames>Lee J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn><gtr:outcomeId>AE4E7B8FCC6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11B21CB1-877E-4E0C-8027-1E21282B6C9F</gtr:id><gtr:title>Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97c941e6447453a3d19c2272f2d74375"><gtr:id>97c941e6447453a3d19c2272f2d74375</gtr:id><gtr:otherNames>Ramsay AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>4496C6EEA91</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EDC928B-A3A9-4468-AE53-140E1CA5F681</gtr:id><gtr:title>Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4e687e7e62db23388559e46d798d39c"><gtr:id>f4e687e7e62db23388559e46d798d39c</gtr:id><gtr:otherNames>Eeles RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>C160EF96F2E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8DA9E9C-05CB-48A3-9E25-C46F1930438B</gtr:id><gtr:title>Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers.</gtr:title><gtr:parentPublicationTitle>Stem cells and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d14425caafb8a9178b4fb46ca6ffeda"><gtr:id>2d14425caafb8a9178b4fb46ca6ffeda</gtr:id><gtr:otherNames>Oates JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1547-3287</gtr:issn><gtr:outcomeId>CBFF8C61B2A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E209FEC5-9879-4682-BF20-38AA675FD211</gtr:id><gtr:title>Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29cf9faaa9394ff68783f0dd3ec1e64b"><gtr:id>29cf9faaa9394ff68783f0dd3ec1e64b</gtr:id><gtr:otherNames>Rigas AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>66C842AF19A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72C16D2D-A628-4488-9D2F-A3A81263B24B</gtr:id><gtr:title>Prostate cancer: regeneration of interest in the prostate.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/740fefd369f7bfef8e3b67d6cc8854e7"><gtr:id>740fefd369f7bfef8e3b67d6cc8854e7</gtr:id><gtr:otherNames>Collins AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>40D41CB73F2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC3ABE8E-4998-4FE9-8944-3E44F19097B6</gtr:id><gtr:title>Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Renal physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ab71b78eb281e7d39c4d8cca5c43f0f"><gtr:id>0ab71b78eb281e7d39c4d8cca5c43f0f</gtr:id><gtr:otherNames>Addla SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1522-1466</gtr:issn><gtr:outcomeId>B89ABC962CA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B9D71D1-74B6-4270-8A75-ECB1D9CE57D2</gtr:id><gtr:title>Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec988e4be99f69a2969f0eb4c5e062d3"><gtr:id>ec988e4be99f69a2969f0eb4c5e062d3</gtr:id><gtr:otherNames>Rowland JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>3734E25C9F1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BBD5CB6-B721-44E6-BCA4-FBB2060D1F10</gtr:id><gtr:title>Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b2598c7689b9d882a916b4182d3eb8e"><gtr:id>4b2598c7689b9d882a916b4182d3eb8e</gtr:id><gtr:otherNames>Birnie R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>BC7C8BCB8D9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39F4A9D4-B0C1-4952-BD6C-9F1512C3F08C</gtr:id><gtr:title>Chromatin immunoprecipitation (ChIP) methodology and readouts.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42f82449a2b9f27ce959a47327c4da62"><gtr:id>42f82449a2b9f27ce959a47327c4da62</gtr:id><gtr:otherNames>Massie CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>C1155267F31</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>525177B5-8AC0-47D0-9AA3-427E41AF9902</gtr:id><gtr:title>Genome-wide association study identifies new prostate cancer susceptibility loci.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fd7a99ad803d87bb45f67651daa6a8f"><gtr:id>0fd7a99ad803d87bb45f67651daa6a8f</gtr:id><gtr:otherNames>Schumacher FR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_15351_21_21743057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D80D10A7-890C-4B81-AA0F-660C2767CD11</gtr:id><gtr:title>Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23ffe610beb51e50bb1847123bae6ac4"><gtr:id>23ffe610beb51e50bb1847123bae6ac4</gtr:id><gtr:otherNames>Thirkettle HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>84EEC11E0E8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42DB993A-0D67-4A4B-A843-F77D651AB8DB</gtr:id><gtr:title>Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63f1dd9fac024b84b36c7dcd9baf0863"><gtr:id>63f1dd9fac024b84b36c7dcd9baf0863</gtr:id><gtr:otherNames>Collin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>684126B43B2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5F2D904-E179-47E0-9411-8300C3A63EC9</gtr:id><gtr:title>Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6991770736449cc3190b4c13d1e92c2"><gtr:id>f6991770736449cc3190b4c13d1e92c2</gtr:id><gtr:otherNames>Avery KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>73378DD2C66</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C29A94D-C55B-444B-9766-CAF5CAA82A0C</gtr:id><gtr:title>Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29cff2bc5eede4dfa03c5cc301a56949"><gtr:id>29cff2bc5eede4dfa03c5cc301a56949</gtr:id><gtr:otherNames>Tilling K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>B42150B0853</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F1D4D17-5209-4FE3-8626-FF8DFC060F81</gtr:id><gtr:title>Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>C17BED8FDC4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C64F881-D028-4559-A7D3-842F7ECBACD2</gtr:id><gtr:title>Biomolecular profiling of metastatic prostate cancer cells in bone marrow tissue using FTIR microspectroscopy: a pilot study.</gtr:title><gtr:parentPublicationTitle>Analytical and bioanalytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d69429222c951d3cd766646e75b77d35"><gtr:id>d69429222c951d3cd766646e75b77d35</gtr:id><gtr:otherNames>Gazi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1618-2642</gtr:issn><gtr:outcomeId>1E35BBDE322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>229DA410-85BE-4053-9865-3BDDF25A93AA</gtr:id><gtr:title>Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56c1a3bdd3f831e3ee00fbd02c9bf827"><gtr:id>56c1a3bdd3f831e3ee00fbd02c9bf827</gtr:id><gtr:otherNames>Camacho N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>5a31d591922e52.99670738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EA0AF94-3035-4F7E-8EA6-E6BB102C9272</gtr:id><gtr:title>Alternative splicing and biological heterogeneity in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/926b354ae4e38e2c054bd1f60c23a749"><gtr:id>926b354ae4e38e2c054bd1f60c23a749</gtr:id><gtr:otherNames>Rajan P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>6D5F9CA0C53</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>022E4E43-9D95-4734-9B30-7E2665426D08</gtr:id><gtr:title>The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aebddcb3a950a46dafb6e76a71689277"><gtr:id>aebddcb3a950a46dafb6e76a71689277</gtr:id><gtr:otherNames>Whitaker HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>BC596781A8F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82866CAA-82A0-4382-B205-4FF6670A2011</gtr:id><gtr:title>Missing channels in two-colour microarray experiments: combining single-channel and two-channel data.</gtr:title><gtr:parentPublicationTitle>BMC bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4883b140d07bd64260513d59027034c"><gtr:id>f4883b140d07bd64260513d59027034c</gtr:id><gtr:otherNames>Lynch AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-2105</gtr:issn><gtr:outcomeId>F1187EE9595</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3082CBC-C5A1-4C08-AB09-E11753B817A4</gtr:id><gtr:title>Editorial comment on: delta-like 1 (Dlk-1), a novel marker of prostate basal and candidate epithelial stem cells, is downregulated by notch signalling in intermediate/transit amplifying cells of the human prostate.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/957b35b6411b395c9dec34a4ac6b4e71"><gtr:id>957b35b6411b395c9dec34a4ac6b4e71</gtr:id><gtr:otherNames>Heer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>E7E820D5F83</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B5B843C-3B70-4BB8-BA2D-44C968C55C6B</gtr:id><gtr:title>Multiple loci on 8q24 associated with prostate cancer susceptibility.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bcfe6bc5eafd47514c917314a7dc3fd"><gtr:id>7bcfe6bc5eafd47514c917314a7dc3fd</gtr:id><gtr:otherNames>Al Olama AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>12ECFBC9F43</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>700DBAAD-BABA-4903-B1C3-4C651B692F85</gtr:id><gtr:title>Genetic correction of PSA values using sequence variants associated with PSA levels.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6de5c1799a3f2818b8594639fb654b94"><gtr:id>6de5c1799a3f2818b8594639fb654b94</gtr:id><gtr:otherNames>Gudmundsson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_15351_21_21160077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>173D071F-E169-46D2-9DAB-0ABA6F0FD1BA</gtr:id><gtr:title>Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ee0f357a0e2776fd8425a5ea7834596"><gtr:id>0ee0f357a0e2776fd8425a5ea7834596</gtr:id><gtr:otherNames>Saunders EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>585d5205a42c03.71653279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CE8F28E-AA19-4216-9927-75BFB4289908</gtr:id><gtr:title>Alterations in beta-catenin expression and localization in prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aebddcb3a950a46dafb6e76a71689277"><gtr:id>aebddcb3a950a46dafb6e76a71689277</gtr:id><gtr:otherNames>Whitaker HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>748819A6761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A5575EF-E787-400B-87CE-EDFC7AA378F5</gtr:id><gtr:title>Spectral discrimination of live prostate and bladder cancer cell lines using Raman optical tweezers.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical optics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c0f8c8d917ac80eaae4d51f5cc28c1e"><gtr:id>9c0f8c8d917ac80eaae4d51f5cc28c1e</gtr:id><gtr:otherNames>Harvey TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1083-3668</gtr:issn><gtr:outcomeId>85F78B6E52A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6520C22-E662-49C2-9DB9-9A4D7F78793E</gtr:id><gtr:title>PTGS2-899G&amp;gt;C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d57f766789defa7c9607aacb29f6e5cc"><gtr:id>d57f766789defa7c9607aacb29f6e5cc</gtr:id><gtr:otherNames>Murad A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>E1111D1AEBC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD45311-13D9-4669-9CF9-70A5850DFF23</gtr:id><gtr:title>Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70862736759c7f4aeb94a67cf6dbe7a2"><gtr:id>70862736759c7f4aeb94a67cf6dbe7a2</gtr:id><gtr:otherNames>Gilbert R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>8B53BA0202C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ADEAC4A-B1B6-468C-B12A-A0169EC55A29</gtr:id><gtr:title>Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d05af7b1f3d52beece455090e63c2d25"><gtr:id>d05af7b1f3d52beece455090e63c2d25</gtr:id><gtr:otherNames>Brown MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>21EBC1EFA86</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6237E273-E7C5-4C59-BB45-CA2B7D4C5EE4</gtr:id><gtr:title>CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee093c3004f2d78532ec497872cfba58"><gtr:id>ee093c3004f2d78532ec497872cfba58</gtr:id><gtr:otherNames>McRonald FE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>B92F1EED997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C71C47D-B998-48FD-9D79-D254454198A8</gtr:id><gtr:title>Survival from prostate cancer in England and Wales up to 2001.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5695006f0a14fdaa8b40cc87ee828535"><gtr:id>5695006f0a14fdaa8b40cc87ee828535</gtr:id><gtr:otherNames>Clarke NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>7693A4C08C9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBA0B55D-1499-45A7-9F3C-F3B9F7F17024</gtr:id><gtr:title>Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc85d919b02f151621e30efefab2e6b6"><gtr:id>cc85d919b02f151621e30efefab2e6b6</gtr:id><gtr:otherNames>Martin RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>65BAA0F0530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBFED843-4CB6-4670-BD41-7C7324F348CA</gtr:id><gtr:title>The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.</gtr:title><gtr:parentPublicationTitle>Journal of cellular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/957b35b6411b395c9dec34a4ac6b4e71"><gtr:id>957b35b6411b395c9dec34a4ac6b4e71</gtr:id><gtr:otherNames>Heer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9541</gtr:issn><gtr:outcomeId>CA02E1114E3</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500966</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>